Half Yearly Report and Accounts
The Group progressed with product delivery despite challenges with marketing progress and activities hampered by the impact of the global coronavirus (COVID-19) pandemic. The Group's sales and marketing team both in Australia and the United States (US) continue to progress negotiations with potential OEMs in the IVF market, cell therapy and target biobanking space with interest for the Company's products and solutions gaining traction.
The Group recently commenced developing its own line of Bluechiip Enabled and Bluechiip branded cryovials and associated products with a focus on selling product directly into North America, Australia & New Zealand and through its distribution channels across the globe. With the reduced sales and marketing activities, the Group focused its activities on the ongoing improvements to the chip performance and efficiency, which it had embarked upon previously and the continuous enhancement of its readers and software.
To view the report, please visit:
About Bluechiip Ltd
Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at http://www.bluechiip.com